NCT06821659View on ClinicalTrials.gov

Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined with Immunosuppressants in the Treatment of Refractory Autoimmune Diseases

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Systemic Lupus ErthematosusSystemic Sclerosis (SSc)Inflammatory MyopathiesANCA Associated Vasculitis (AAV)Sjogren Syndrome
Interventions
BIOLOGICAL

anti-CD19 CAR-T cells

UWD-CD19

All Listed Sponsors
lead

Peking University Third Hospital

OTHER

NCT06821659 - Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined with Immunosuppressants in the Treatment of Refractory Autoimmune Diseases | Biotech Hunter | Biotech Hunter